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The modulatory role of allosteric receptor-receptor interactions in the pain pathways of the Central Nervous System and the
peripheral nociceptors has become of increasing interest. As integrators of nociceptive and antinociceptive wiring and volume
transmission signals, with a major role for the opioid receptor heteromers, they likely have an important role in the pain circuits
and may be involved in acupuncture. The delta opioid receptor (DOR) exerts an antagonistic allosteric influence on the mu opioid
receptor (MOR) function in aMOR-DOR heteromer.This heteromer contributes to morphine-induced tolerance and dependence,
since it becomes abundant and develops a reduced G-protein-coupling with reduced signaling mainly operating via 𝛽-arrestin2
upon chronic morphine treatment. A DOR antagonist causes a return of the Gi/o binding and coupling to the heteromer and the
biological actions of morphine.The gender- and ovarian steroid-dependent recruitment of spinal cordMOR/kappa opioid receptor
(KOR) heterodimers enhances antinociceptive functions and if impaired could contribute to chronic pain states in women.MOR1D
heterodimerizes with gastrin-releasing peptide receptor (GRPR) in the spinal cord, mediating morphine induced itch. Other
mechanism for the antinociceptive actions of acupuncture along meridians may be that it enhances the cross-desensitization of the
TRPA1 (chemical nociceptor)-TRPV1 (capsaicin receptor) heteromeric channel complexes within the nociceptor terminals located
along these meridians. Selective ionotropic cannabinoids may also produce cross-desensitization of the TRPA1-TRPV1 heteromeric
nociceptor channels by being negative allosteric modulators of these channels leading to antinociception and antihyperalgesia.
1. Introduction
The monoamine-peptide interactions have been of great
interest [1]. How did they, in fact, interact at the molecular
level? One possibility was that the monoamine and pep-
tide signals became integrated through direct neuropeptide-
monoamine receptor-receptor interactions in the plasma
membrane. We began to test this hypothesis in 1980-1981 in
membrane preparations of various Central Nervous System
(CNS) regions and found that neuropeptides could modulate
the binding characteristics, especially the affinity, of the
monoamine receptors in a receptor subtype specific way
[2, 3]. Thus, intramembrane receptor-receptor interactions
did exist besides indirect actions via phosphorylation and
changes in membrane potential. The results were in line
with earlier findings by Limbird et al. in 1975, showing
negative cooperativity in 𝛽-adrenergic receptors, which may
be explained by the existence of receptor homodimers leading
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to orthosteric site-site interactions [4]. It was also clear that
adapter proteins can be involved in mediating the receptor-
receptor interactions in brain membranes [5, 6].
In this paper we give a brief overview of the modulatory
role of receptor heteromers in the pain pathways in the CNS
and in peripheral nociceptors. They seem to be integrators
of nociceptive and antinociceptive wiring (WT) and volume
transmission (VT) signals with a major role for the opioid
receptor heteromers. Their relevance in the mechanisms for
the antinociceptive actions of acupuncture will be discussed.
2. Primary Afferents of the Dorsal Horn
Mediating Nociception
We have different types of nociceptors coming into the dorsal
horn (primary afferent fibres). One major class includes
medium diameter myelinated (A𝛿) afferents that mediate
well-localized fast pain. The second class of nociceptor
includes small diameter unmyelinated “C” fibers thatmediate
poorly localized, slow pain [7]. There exist a very precise
laminar organization of the dorsal horn of the spinal cord.
Theunmyelinated, peptidergic C andmyelinatedA𝛿nocicep-
tors terminate most superficially, synapsing upon large pro-
jection neurons in lamina I and interneurons located in outer
lamina II.Thus, primary afferent nociceptors convey noxious
information to projection neurons within the dorsal horn of
the spinal cord (Figure 1, left).
3. Pain Pathways and Their
Regulation through WT and VT Signals
Integrated through Receptor-Receptor
Interactions in Heteromers
A subset of these projection neurons transmits information
to the somatosensory cortex via the thalamus, providing
information about the location and intensity of the painful
stimulus [7]. Other projection neurons reach the cingulate
and insular cortices via relay stations in the lower brainstem
(parabrachial nucleus) and amygdala, contributing to the
emotional component of the pain experience (Figure 1, left).
This ascending information also passes on to neurons of the
rostral ventral medulla, including the raphe and pararaphe
area and the periaqueductal gray of the midbrain to activate
descending feedback systems like distinct bulbo-spinal sero-
tonin (5-HT) and noradrenergic (NA) neurons [8] that regu-
late the pain transmission output from the spinal cord, espe-
cially the lateral paragigantocellular reticular 5-HT neurons
may be involved in this process.
This important descending inhibitory control of noci-
ception in the dorsal horn of the spinal cord (Figure 1, left)
involves especially the periaqueductal gray-rostral ventrome-
dial medulla, the dorsal reticular nucleus of the medulla, and
the ventrolateral medulla [9]. The descending bulbo-spinal
NA and 5-HT neuron systems [10–12] play a substantial role
[13–15]. Noxious stimulation excites the 5-HT neurons of the
lateral paragigantocellular reticular and raphe magnus nuclei
[16], building up group B3 of Dahlstroem and Fuxe [10] and
these 5-HT neuron systems produce strong analgesia and
the former also cardiovascular activation. Also descending
projections to the dorsal horn from DA neurons in the
posterior hypothalamus participate in control of pain [17].
The major descending inhibitory bulbo-spinal systems are
under the control of high densities of mu opioid receptors
[18, 19]. Blockade of the opioid receptors in the medullary
reticular nucleus dorsalis prevents analgesia produced by
diffuse noxious inhibitory controls [20].The anti-nociceptive
actions of the descending inhibitory pathways in the spinal
cord involves the indirect activation of opioid receptors in
the dorsal horn, especially in the superficial layers. The
major mode of communication in the descending inhibitory
monoamine pathways of nociception is extrasynaptic volume
transmission involvingmonoamine diffusion in the um range
[21] and activation of their extrasynaptic receptors located
on the nociceptors and their target nerve cells mainly found
in the superficial layers in the dorsal horn. However, wiring
transmission also exists in these descending systems through
formation of monoamine synapses. When neuropeptides are
released from these descending inhibitory pathways long
distance volume transmission can develop in the order of 0.1–
1mmand also involve CSF volume transmission provided the
peptides do not undergo rapid degradation [22].
In these pain circuits wewill describe howopioid receptor
containing heteromers may play a role in the modulation of
pain transmission, offering novel targets for antinociceptive
drugs.Theymay be involved in conveying the antinociceptive
actions of acupuncture [23] since inter alia electroacupunc-
ture has been shown to increase transcription and translation
of enkephalins in the rostral ventrolateral medulla of rats,
a region involved in regulation of not only circulation and
respiration but also pain [24]. The enkephalin peptides
(short distance diffusion) and 𝛽-endorphin (long distance
diffusion)mainly operate via VT [25–27] and likelymodulate
the pain circuits via receptor-receptor interactions in receptor
heteromers built-up of synaptic protomers and of opioid
receptor protomers. In this way synaptic transmission signals
and VT signals become integrated giving a balance in noci-
ceptive and antinociceptive signaling in the CNS (Figure 1).
4. Principal Features of
the Receptor Heteromers
As mentioned in the introduction, the concept of intramem-
brane receptor-receptor interactions in receptor heteromers
was born in the analysis of neuropeptide-monoamine
receptor-receptor interactions in 1980-81. The concept of
G protein-coupled receptor (GPCR) heteromers was later
confirmed in 1998-1999 by studies reporting that two non-
functional GPCR monomers, gamma amino butyric acid
(GABA)B1 and GABAB2 receptors, can assemble in a sig-
nalling heterodimer, the GABAB receptor at the cell surface
[28, 29].
5. The Receptor-Receptor Interaction Toolbox
5.1. Fluorescence and Bioluminescence Resonance Energy
TransferMethods. Different resonance energy transfermeth-
ods have been used to study the existence of GPCR
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Figure 1: Pain pathways and their regulation through WT and VT signals integrated through receptor-receptor interactions in heteromers.
(left) A schematic overview of the ascending main circuits mediating pain. When a noxious stimulus is encountered. Afferent nociceptors
convey noxious information to projection neurons within the dorsal horn of the spinal cord. Neurotransmitters released here bind to
and activate postsynaptic receptors on pain transmission neurons. In turn, the axons of pain transmission neurons ascend, predominantly
contralaterally, to the brain and carry the information about the noxious stimulus to higher centers (somatosensory cortex via the thalamus
with information about location and intensity of the painful stimulus or the insular cortices via connections in the brainstem (parabranchial
nucleus) and amygdala within the affective component of the pain experience). The descending inhibitory pathways to the dorsal horn from
the brainstem involving interalia the NA, 5HT, and DA pathways (see text) are also indicated. They exert antinociceptive actions in the pain
circuits of the dorsal horn. (right) The diagram shows a few prominent of many possible mediators and cell-cell interactions in the spinal
cord dorsal horn, thalamus, or amygdala. In these pain circuits opioid receptor containing heteromers may play a role in the modulation of
pain transmission, offering novel targets for antinociceptive drugs.The enkephalin peptides (short distance diffusion) and b-endorphin (long
distance diffusion) mainly operate via VT and likely modulate the pain circuits via receptor-receptor interactions in receptor heteromers
built-up of synaptic protomers and of opioid receptor protomers. In this way synaptic transmission signals and VT signals become integrated
giving a balance in nociceptive and antinociceptive signaling in the CNS. The descending inhibitory pathways to the dorsal horn involving
inter alia the monoamine pathways also mainly communicate via VT (see text).
heteromers [30–33]. Fluorescence resonance energy transfer
(FRET) method using for example, the CFP-YFP pair in the
labeling of two receptors. If the receptors physically interact
the distance is short enough (10 nm or less) to allow energy
transfer from the donor CFP on one receptor to the acceptor
YFP on the other receptor, thus a FRET signal develops from
YFP. At the cell surface in living cells, the time-resolved
FRET (TR-FRET) method have been developed to study
receptor heteromers, by conjugating donor and acceptor
fluorophore molecules to antibodies against each protomer
in the heteromer of interest. TR-FRET is based on the
engagement of a resonance energy transfer process between a
lanthanide, such as europium (Eu3+) or terbium (Tb3+) cryp-
tate, as a donor molecule and a compatible acceptor chro-
mophore, such as alexafluor 647 or allophycocyanin [30].
Principle of the detection of GPCR heterodimerization
using the bioluminescence resonance energy transfer BRET
method is similar to the FRET method except a Renilla
luciferase-GFP
2
/YFP pair is used in the tagging of the two
receptors, in the presence of the substrate h-coelenterazine
or coelenterazine-400 on which Renilla luciferase acts to
produce through oxidation a bioluminescent signal.Then the
energy transfer between the generated luminescence andYFP
or GFP
2
occurs when the distance between these proteins is
less than 10 nm leading to a fluorescence emission from YFP
or GFP
2
[21].
On the other hand, the principle of bimolecular fluores-
cence complementation (BiFC)methods is based on the com-
plementation of the N-terminal and C-terminal fragment of
a fluorescent protein (e.g., YFP) [34]. After interaction of the
tagged receptors, the protein fragments reconstitute a func-
tional fluorescent protein interpreted as a result of GPCR
heteromer formation.
A drawback of these methods is the fact that they involve
the ectopic expression and/or overexpression of the fusion
receptors, thereby, sometimes promoting the formation of
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Figure 2: Intra- and intermolecular allosteric receptor-receptor interactions. Allosteric mechanisms make possible the integrative activity
taking place intramolecularly in monomers (left) or intermolecularly in homo-/heteromers (right). As one example of the intramolecular
allosteric mechanisms is the allosteric binding of salvinorin A to the extracellular site of MOR, which partially affects the activity of the
orthosteric MOR binding site via a conformational change [105]. Intermolecular allosteric mechanisms take place through the formation
of different types of receptor homo-/heteromers and receptor/protein complexes which can change the function of an individual receptor
present in a homomer or heteromer. Another example based on the intermolecular heteromer interactions is the use of heterobivalent ligands
containing a MOR agonist and an DOR antagonist linked through a spacer of variable size which may function as useful molecular probes
for targeting the MOR-DOR heteromer and in this way counteracting the DOR antagonism onMOR function. Such compounds may have a
potential use in pharmacotherapy of pain.
artefacts. It is therefore advisable, whenever possible, to
consider the physiological expression levels of the receptor
pairs under study.
5.2. In Situ Proximity Ligation Assay. However, despite exten-
sive experimental results supporting the formation of GPCR
heteromers in heterologous systems (mainly by BRET and
FRET methodologies), the existence of such heteromers in
the CNS and other tissues remains largely unknown, mostly
because of the lack of appropriate methodology. Recently,
a well-characterized in situ proximity ligation assay (in situ
PLA) has been adapted to confirm the existence of GPCR
heteromers in brain slices ex vivo [35–39].
In situ PLA is based on a pair of antibodies that can bind
to target proteins and to which oligonucleotides have been
attached. When the so-called proximity probes recognize
a target, for example, the receptor heteromer, the attached
oligonucleotides are brought into a sufficiently close spatial
proximity to allow them to join followed by ligation of the two
linear oligonucleotides into a circular DNA molecule. This
newly formed DNA circle strand can serve as a template for
rolling circle amplification (RCA), resulting in a long single-
stranded rolling circle product (RCP) attached to one of the
proximity probes. Since the RCP is linked to the proximity
probe, it is attached at the site where the proximity probe
bound, which means that it can be used to reveal the location
of the receptor complex [40, 41]. The RCPs can then be
detected and quantified by hybridizing fluorescent oligonu-
cleotides to the repeated sequences of the RCPs, rendering
them visible by fluorescence microscopy. With the in situ
PLA method the striatal adenosine 2A receptor (A2AR)-
dopamine D2 receptor (D2R) heteromers and D2R-oxytocin
receptor heteromers have for example, been shown [35, 39].
Also the hippocampal and the mesencephalic raphe FGFR1-
5-HT1AR heteromers have recently been demonstrated [36,
37]. The in situ PLA procedure represents a high selectivity
and sensitivity assay to demonstrate GPCR heteromers in
brain [38].
6. Allosteric Receptor-Receptor Interactions
In the beginning, allosteric mechanisms were only discussed
in terms of intramolecular interactions within a receptor
between orthosteric and allosteric sites. This was the classic
pharmacology (Figure 2, left).
Now we have moved into a novel pharmacology, where
intermolecular receptor-receptor interactions can occur and
results in novel receptor recognition, pharmacology and
signaling (Figure 2, right). Intermolecular allosteric mecha-
nisms through the receptor interface produce these changes
involving also receptor/protein complexes. An example of
the novel pharmacology is the use of heterobivalent ligands
[42–44] containing, for example, MOR agonist and DOR
antagonist pharmacophores linked through a spacer of vari-
able size which may function as useful molecular probes
for targeting the MOR-DOR heteromer and in this way
counteracting the DOR antagonism on MOR function [43]
(Figure 2, right). Such compounds may have a potential use
in pharmacotherapy of pain.
Allosteric mechanism causes a marked rise of the reper-
toire of GPCR recognition, pharmacology, trafficking and
signaling of the participating protomers. This is achieved
through changes in recognition, G protein selectivity, and
signaling cascades with among others switching from G
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proteins to 𝛽-arrestin or to calmodulin [33, 45]. Its function
may also change by becoming linked to Receptor Tyrosine
Kinases (RTKs) or to ion channel receptors [36, 37, 46].
The term moonlighting protein is used to describe
multifunctional proteins in which several functions can be
found in a single strand of amino acids unrelated to splicing,
posttranslational changes, and so forth [47, 48]. In GPCR
heteromers moonlighting is brought about by the allosteric
receptor-receptor interactions altering the function of the
receptor protomers of the heteromer through conformational
changes in single strands of amino acids [46].
7. The Receptor Interface
We are interested in the receptor interface since it can be
a target for novel drugs by their ability to block or mimic
the allosteric receptor-receptor interactions [21, 49–51]. The
interface in the A2AR-D2R heteromer can be given as an
example [50, 51]. It shows helix-helix interactions in the
plasma membrane between A2AR TMIV and D2R-TMV.
Intracellular electrostatic interactions between D2R IC3 and
A2AR C-terminal tail involve positively charged arginines
in the D2R IC3 and negatively charged residues in the
A2AR especially phosphorylated serine [50–54]. Electrostatic
interactions may represent important hot spots in the recep-
tor heteromer interface. The prototype was the A2AR-D2R
heteromer but it exists also in theA2AR-D3R andA2AR-D4R
interface [55], giving an amazing stability of the heteromers
based on the arginine-phosphate bond [54].
Based on a mathematical approach developed by Dr.
Tarakanov, we have deduced, based on 48 pairs of receptors
that form or not form heterodimers, a set of triplet amino
acid homologies that may be critically involved in receptor-
receptor interactions [56]. We call it the triplet puzzle. We
showed how such triplets of amino acid residues and their
“teams” may be used to construct a kind of code that help
determinewhich receptors should or should not formhetero-
dimers.We propose a “guide-and clasp” manner for receptor-
receptor interactions where “adhesive guides” may be the
triplet homologies [57–60].
The pro-triplet theory has recently became validated [61,
62] underlining its impact on understanding the receptor
interface of the heteromers. On the other hand, the pro-
posed contra-triplets, postulated to block the formation of
heteromers, still remain to be documented through experi-
mental work. The lack of studies based on the specificities of
the established heteromers hamper a proper prediction of the
proposed contra-triplets, that now can be optimized through
new experimental data.
8. On the Existence of MOR, DOR,
and KOR and Their Participation in
Receptor Heteromers
The MOR, DOR, and KOR and their heteromers are of spe-
cial interest since they play a major role in mediating the
antinociceptive transmission of the enkephalin and 𝛽-endo-
rphin neurons in case of MOR and DOR and of the dynor-
phin neurons in case of KOR (Figure 3). It is known from the
fine work of the Watson group that the DOR and especially
MOR have a widespread distribution in the brain including
the regions of the pain circuits [63]. There exist partial
overlaps in the brain and spinal cord of the distribution of
theMORandDOR systems.Awidespread distribution is true
also for KOR that partially overlaps with the MOR and DOR
distribution in the brain and spinal cord. Pain control is all
about the balance of activity in the pain and anti-pain systems
in the spinal cord, the brainstem, the thalamus, the limbic
system and the somato-sensory cortex.
The first opioid receptor heteromer to be discovered was
the DOR-KOR heteromer in 1999 by Jordan and Devi [64].
Then in 2000, the MOR-DOR heteromer was demonstrated
by George et al. [65] and in 2010 the MOR-KOR heteromer
was identified in spinal cord membranes by Chakrabarti et
al. [66] and found to be sex specific. They all participate in
the modulation of pain.
Together with the existence of opioid heteromers, alter-
native splicing of the opioid receptor subtypes may help to
reconcile the differences between pharmacological subtypes
and the results by molecular cloning of only three opioid
receptor subtypes. However, also other mechanisms partici-
pate [67]. The formation of different types of opioid receptor
heteromers through allosteric mechanisms over the receptor
interface may contribute to the binding of receptor interact-
ing proteins, producing additional pharmacological subtypes.
This can involve, in the latter case, allosteric mechanisms in
the receptor-protein interface.
9. MOR-DOR Heteromers and Their
Modulation of Pain Circuits
Earlier findings showed that there exist some MOR ago-
nist/DOR antagonist interactions in morphine actions that
can be explained by the existence and function of the MOR-
DOR heteromer [68], namely, the following.
(i) Selective DOR blockade with a DOR antagonist
reduces the development of morphine tolerance and
dependence.
(ii) Chronic administration of morphine results in an
upregulation of DORs in rats.
(iii) The intensity of the withdrawal syndrome after
chronic morphine treatment correlates with the level
of DOR binding sites.
(iv) An antisense oligodeoxynucleotide to DOR was
shown to prevent the development of morphine
tolerance and dependence after chronic morphine
administration [69].
(v) In DOR knockout mice morphine retained its MOR-
mediated analgesic activity without producing toler-
ance with chronic administration.
All these findings can be explained by DOR exerting an
antagonistic allosteric influence on the MOR function in a
MOR-DOR heteromer.
In line with the results summarized above, acute in
vitro experiments on MOR-DOR heteromers in cell lines
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Figure 3: Receptor-receptor interactions in different types of opioid receptor heteromers in the CNS and their potential role in
pharmacotherapy of pain. The homo- and heterodimers would allow direct physical interactions between the receptors making possible the
allosteric receptor receptor interactions between them.The functional balance between these oligomers determines the final functional output
and thus the eventual cellular response. The schematic representation depicts some of the principal, nonexclusive, molecular mechanisms by
which opioid heteromers produce novel functions.
give evidence that the DOR antagonist enhances MOR
recognition, Gi/o coupling and inhibition of cAMP levels.
These actions correlatedwith potentiatedmorphine analgesia
[70].
9.1. Hypothesis on the Role of the MOR-DOR Heteromer in
Opioid-Induced Tolerance and Dependence. An interesting
concept was introduced by Rozenfeld et al. in 2007 [71] to
show the difference in the signaling of MOR homomers
versus MOR-DOR heteromers upon repeated morphine
treatment. You have a mixture of MOR heteromers and
homomers in the plasma membrane and the MOR homod-
imer activation leads to a rapid G protein-mediated ERK1/2
phosphorylation. pERK1/2 goes to the nucleus, where it acti-
vates transcription factors contributing to morphine induced
analgesia. Instead in the MOR-DOR heterodimer increasing,
under chronicmorphine treatment, the allostericmechanism
is different. It has switched the coupling from G protein to
𝛽-arrestin2. You have instead a slow 𝛽-arrestin2-mediated
ERK1/2 phosphorylation. pERK is retained in the cytoplasm
and activates cytoplasmic substrates, such as p-p90srk
(Ribosomal protein S6 kinase, 90 kDa) with reductions of
changes in gene expression and reduction ofmorphine action
[72].
Also a time course difference in the MOR homodimer
versus MOR-DOR heterodimer mediated ERK phosphoryla-
tion in primary dorsal root ganglion neurons was measured.
Cotreatment of the heterodimer with a combination of a
MOR agonist and a DOR antagonist after chronic treatment
with morphine leads through altered allosteric receptor-
receptor interaction to a dissociation of 𝛽-arrestin2 from
the heteroreceptor complex and return of the Gi/o binding
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and coupling to the heteromer and the biological actions of
morphine. It may also be associated with a certain disruption
of MOR-DOR heteromers into MOR homomers increasing
the MOR homomer/MOR-DOR ratio (Figure 3).
9.2. Experimental Evidence for Targeting the MOR-DOR Het-
eromer as a Strategy in AntinociceptiveTherapy. Based on the
hypothesis stated above of an increased formation of MOR-
DOR heteromers upon chronic morphine treatment con-
tributing to morphine induced tolerance and dependence,
novel bivalent compounds with a MOR agonist pharma-
cophore and DOR antagonist pharmacophore have been
developed [43]. Furthermore, opioid-induced tolerance and
dependence in mice is modulated by the distance among
pharmacophores in a bivalent ligand series, several being
substantially more potent than morphine. It offers a new
approach for the development of analgesics devoid of tol-
erance and dependence. One problem with some bridged
bivalent compounds is that they may reduce dissociation
of the MOR-DOR heteromer and exert a negative allosteric
influence on MOR signaling in spite of the block produced
by the delta opioid antagonist at the orthosteric site of the
DOR.
9.3. Effects of Chronic Morphine Treatment on the MOR-DOR
Heteromer in the CNS. The above hypothesis is now also
supported by new evidence. Gupta and colleagues have found
increased abundance ofMOR-DOR heteromers after chronic
morphine administration [73]. Chronic, but not acute, mor-
phine treatment caused an increase in the abundance of
MOR-DOR heteromers in key areas of the CNS that are
implicated in pain processing. Because of its distinct signaling
properties, theMOR-DORheteromermay, as outlined above,
be a therapeutic target in the treatment of chronic pain and
addiction [73].
This fine piece of work was possible through a subtractive
immunization strategy to generate antibodies that selectively
recognize the endogenous MOR-DOR heteromer but does
not recognize either MORs or DORs [74]. Such heteromer
specific antibodies may also block or activate the heteromer
without influencing the homomer adding to their use as tools
in the analysis of the function of these heteromers. Increases
could be observed in the rostral raphe region of the medulla
oblongata, rich in 5-HT neurons projecting to the dorsal
horn, as well as in areas of relevance to reward andmood like
ventral tegmental area, nucleus accumbens, prefrontal cortex
and hippocampus.
All the data support a role of this heteromer in morphine
tolerance and dependence, since this heteromer develops
a reduced G protein-coupling with signaling mainly oper-
ating via 𝛽-arrestin2 (see above). Treatment with DOR
antagonists reduces the 𝛽-arrestin2 coupling in the MOR-
DOR heteromer and enhances MOR binding, signaling
and morphine-induced antinociception; which may enhance
MOR-DOR disruption. It will be of substantial interest to
study if acupuncture could favor the formation of MOR
homomers versus MOR-DOR heteromers during chronic
morphine treatment.
10. MOR-KOR Heteromers and
Their Involvement in Gender and
Ovarian-Steroid Dependent
Antinociceptive Actions
The field of MOR-KOR heteromers is also exciting. Forma-
tion of MOR-KOR heterodimer is gender-dependent and
mediates female-specific opioid analgesia [66] (Figure 3).
Spinal morphine antinociception in females, but not males,
required the concomitant activation of spinalMORandKOR.
The evidence shows that spinal cord expression of the MOR-
KOR heterodimer is sexually dimorphic and dependent on
the stage of the estrous cycle. It is elevated in proestrus with
high estrogen receptor (ER) levels as seen from coimmuno-
precipitation studies obtained with anti KOR antibodies on
the spinal cord [66].
The evidence also shows that the contribution of dynor-
phin/KOR (part of MOR-KOR heterodimer) to spinal mor-
phine antinociception is dependent on the stage of the
ovarian cycle [66, 75]. Spinal morphine antinociception
was quantified using the tail-flick test during diestrus and
proestrus. The dynorphin antibody and the KOR antago-
nist counteracted the morphine-induced anti-nociception in
proestrus but not in diestrus. Dynorphin was shown to be
linked to the KOR protomer of the MOR-KOR heteromer. It
represents a molecular switch that shifts the function of KOR
and thereby endogenous dynorphin from pronociceptive to
antinociceptive actions. Thus, KOR-MOR heteromer could
be a novel molecular target for pain control in women.
Further work has indicated that spinal synthesis of estro-
gen and concomitant signaling by membrane ER regulate
spinal MOR-KOR heterodimerization and female-specific
spinal morphine antinociception [76, 77]. There exists coex-
pression of MOR-IR (immunoreactivity) with ER alpha (ER-
alpha), GPR30 (a GPCR for estrogen), or KOR in the super-
ficial dorsal horn. Colocation of MOR-IR and ER-alpha-IR,
MOR- and GPR30-IR and MOR-KOR-IR is found in nerve
cell bodies and fibers in the superficial dorsal horn. Thus,
MOR, KOR, ER-alpha, and GPR30 appear to be coexpressed
in neurons of the spinal dorsal horn [76].
Biochemical and behavioral experiments suggest that ERs
work in a cooperative manner as part of a macromolecular
complex to increase KOR/MOR expression. Estradiol (E2)
(spinally synthesized and ovarian derived) triggers the for-
mation of a signaling complex that containsmultiple ERs and
enhances heterodimerization of KOR and MOR. Transcrip-
tional effects of progesterone (P4) are essential either for the
formation of the ERs signaling complex and/or the hetero-
dimerization of KOR with MOR [76, 77].
In our view the formation of receptormosaics of activated
membrane ER complexes and MOR and/or KOR may take
place markedly enhancing the formation of MOR-KOR het-
eromers in the plasma membrane through allosteric changes
in MOR and/or KOR. Possibly, progesterone may contribute
through transcriptional increases of opioid receptor inter-
acting proteins that may be essential for the MOR-KOR
heteromer formation from the ERs-MOR and/or ERs-KOR
heteromer complexes.
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In summary, the gender- and ovarian steroid-dependent
recruitment of spinal cord MOR-KOR heterodimers would
provide a way to influence the balance between antinocicep-
tive and pronociceptive functions of the spinal dynorphin/
KOR opioid system. Impaired formation of MOR-KOR het-
eromers could be a biological determinant of various types
of chronic pain states that are substantially more common in
women than men [66].
11. Opioid Receptor-Like 1 Receptor
Heterodimerize with Other Members of
the Opioid Receptor Family
The nociceptin receptor or opioid receptor-like receptor 1
(ORL1) belong to the class of Gi/o-linked receptors [78, 79]
and is activated by the endogenous 17 amino acid polypeptide
ligand orphanin FQ (nociceptin). ORL1 heterodimerize with
the other members of the opioid receptor family and can
cointernalize each one of them upon agonist exposure.
Upon dimerization with opioid receptors, ORL1 regula-
tion of N-type calcium channels is altered. ORL1 can function
as a molecular link that allows MORs to trigger N-type cal-
cium channel internalization [80]. Thus, MOR-ORL1 hetero-
dimers are shown to associate with N-type calcium channels,
with activation ofMORs triggeringN-type channel internali-
zation, but only in the presence of ORL1. Evans et al. [80]
found that when coexpressed with the channels alone, ORL1
could trigger internalization of the N-type channels in a
nociceptin dose-dependent manner. Without ORL1 expres-
sion, activation of MORs by DAMGO did not affect N-
type channel surface expression, consistent with a lack of
internalization. However, when both MOR and ORL1 were
coexpressed,DAMGOapplication resulted in a dose-depend-
ent loss of N-type channels from the cell surface but not as
marked as with ORL1 alone.These findings give the evidence
that ORL1 serves as a molecular link allowingMORs to regu-
late N-type channel surface expression.
These results are of high interest since opioid and opioid-
like receptors play a key role in controlling pain signaling
in primary afferent terminals in the dorsal horn by two pri-
mary mechanisms [81, 82]. These mechanisms are activation
of G protein-coupled inwardly rectifying potassium chan-
nels, and inhibition of N-type calcium channels in nerve
terminals within the dorsal horn of the spinal cord, both
reducing neuronal excitability. In conclusion, formation of
opioid/ORL1 heterodimers exerts a profound effect on noci-
ceptive processing [80].
Looking at the primary afferents to the dorsal horn clearly
activated C and A𝛿 nociceptors release a variety of neuro-
transmitters, activating output neurons in lamina I of the
dorsal horn forming part of the pain pathways from the dorsal
horn. One important location of the opioid-ORL1 heteromers
may therefore be at the central terminals of these noci-
ceptors to inhibit release of transmitters from them involv-
ing increased internalization of the N-type Ca2+ channels as
well as activation of inwardly rectifying K+ channels. Again it
would be of high interest to explore how acupuncture would
modulate the formation of these receptor heteromeric com-
plexes in the dorsal horn.
12. Do the Alpha-2A Adrenergic
Receptor-MOR Heteromers Have a Role
in Pain Processing Pathways?
Early work indicates that agonists acting at the alpha-
2A adrenergic receptor subtype (alpha-2AAR) and opioid
receptors have analgesic properties and act synergistically
when co-administered in the spinal cord. The alpha-2AAR
subtype is the primary mediator of alpha2 adrenergic spinal
analgesia and is necessary for analgesic synergy with opioids
and feedback inhibition of capsaicin-induced hyperalgesia
[83, 84]. Other findings also demonstrated that alpha-2AAR
potentiated morphine analgesia. Thus, a mutual potentiation
of anti-nociceptive effects of morphine (opioid agonist) and
clonidine (alpha-2AAR agonist) was demonstrated between
the antinociceptive effects of intrathecal clonidine and sys-
temic morphine which may be effective in the treatment of
chronic pain states [85–87].
The question is if alpha-2AAR-MOR heteromers can
participate in these synergistic actions? The major origin of
NA innervation of the dorsal horn by the descending bulbo-
spinal NA systems [10, 12] is the locus coeruleus (LC) [11]. NA
or clonidine significantly reduces the evoked release of glu-
tamate from spinal cord synaptosomes [88] and the release
of substance P (SP)-like material and calcitonin gene related
peptides (CGRP) from spinal cord slices [89]. Such actions
could explain the antinociceptive actions of alpha-2AAR
activation.
Immunoreactivity for both alpha-2AAR and MOR is
observed in the superficial layers of the dorsal horn of the
spinal cord. The primary localization of the alpha-2AAR in
the rat spinal cord is on the terminals of capsaicin-sensitive,
SP-containing primary afferent fibers (colocation with MOR
IR). Thus, alpha-2AAR-MOR heteromers may exist on these
terminals.
The role of the receptor-receptor interactions in the
alpha-2AAR andMOR heteromers was found to be an unex-
pected one [90]. There exists a conformational antagonistic
crosstalk between alpha-2AAR and MORs in their control
of cell signaling upon coactivation (Figure 3). Activation of
MOR by morphine modulates alpha-2AAR signaling by a
direct strong antagonistic conformational change that propa-
gates from MOR to alpha-2AAR within 0.4 s. The inhibition
of Gi activation in the reverse direction also suggests a
conformational propagation from alpha-2AAR to MOR.
The conformational spread conveyed by the two agonists,
noradrenaline and morphine leads to functional inhibition
upon agonist coactivation, called cross-inhibition [90]. This
is likely a means of rapidly preventing overstimulation of
the same signaling pathway as also discussed for alpha-
2AAR-Neuropeptide Y receptor (NPY receptor) interactions
[91], which results in a cross-inhibition of alpha-2AAR and
NPY receptors, both coupled to Gi/o, in biochemical and
functional studies on vasodepressor responses. These studies
may serve as a model for understanding fast desensitization
mechanisms in several signaling pathways.These results sug-
gest that combined agonist activation of alpha-2AAR-MOR
heteromers could play a role in counteracting excessive anal-
gesia.
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It follows that synergy of alpha-2AAR agonist and mor-
phine in antinociception cannot be explained by receptor-
receptor interactions in the alpha-2AAR-MOR heteromers.
In this case, interactions at the level of signaling pathways and
ion channels controlled by the corresponding homomersmay
be involved as well as a location in different nerve cells of the
neuronal network synergizing in favoring an output pathway
leading to antinociceptive effects.
13. On the Localization and Functional
Roles of Cannabinoid CB1 Receptors in
Pain-Processing Pathways
Synergistic interactions also exist between cannabinoid and
opioid analgesia [92]. The cannabinoid CB1 receptors (CB1)
are activated by the endocannabinoids, 2-arachidonoylgly-
cerol (2-AG) and anandamidewhich are recognized formedi-
ating retrograde signaling at glutamate and GABA synapses
mediating depression of depolarization induced suppression
of excitation and of inhibition, respectively [93]. They likely
communicate via an extracellular vesicle mediated form of
VT [94, 95]. They can be formed by budding from lipid rafts
(shedding vesicles) and may impinge on the plasma mem-
brane of target cells to transfer lipid rafts with associated
receptor oligomeric complexes and lipid messengers like the
endocannabinoids.
CB1s are present at many locations in the pain networks
namely in peripheral terminals of primary sensory neurons,
at synapses in the spinal cord, and in pain circuits of the brain.
At spinal synapses, CB1 could be on nerve terminals of affer-
ent neurons, on interneurons, and/or on terminals of path-
ways originating in supraspinal regions [96].
A strong colocalization of CB1 and MOR has been
observed in lamina II interneurons [97]. The CB1 action
can also involve the inhibition of N-type Ca2+ channels and
activation of inwardly rectifyingK+ channels in afferent term-
inals and dorsal horn neurons as discussed for the alpha-
2AAR and MORs.
14. On the Role of CB1-MOR Heteromers for
Neuroplasticity in Pain Pathways
Rios et al. in 2006 demonstrated that CB1 forms heteromers
with opioid receptors [98]. A BRET signal is formed with
MOR, DOR and KOR in cellular models. Thus, coexpression
of opioid receptors with CB1, but not with chemokine recep-
tors, leads to a significant increase in the level of BRET signal
giving evidence for the existence of CB1-opioid receptor
heteromers (Figure 3).
Simultaneous activation ofMOR andCB1 leads to a signi-
ficant attenuation of the increase in MAPK phosphorylation
response seen upon activation of the individual protomers.
Thus, upon agonist coactivation antagonistic receptor-re-
ceptor interactions develop in the CB1-MOR heteromers as
observed for the alpha-2AAR-MOR heteromers. However,
when the CB1 protomer alone is activated in the CB1-MOR
heteromer there is a marked increase in signaling compared
with the agonist activation of CB1 monomer/homomer.
Similar results were obtained on neurite outgrowth in
Neuro-2A cells expressingMOR and CB1 ’s. Agonist-induced
neurite outgrowth in Neuro-2A cells treated with a combi-
nation of 100 nM DAMGO or morphine, and 100 nM CB1
agonist HU-210 is markedly reduced upon coactivation while
increased with single agonist activation. Upon coactivation a
substantial cross-inhibition of the phosphorylation of Src and
STAT3 is observed [98].
Antagonistic allosteric interactions in CB1-MOR het-
eromers may underlie the attenuation of the Src-STAT3 path-
way signaling which could be one of the mechanisms leading
to reduction of neurite outgrowth. MOR-CB1 interactions
will thus upon coactivation lead to cross-inhibition of neu-
ritogenesis involving inhibition of the Src-STAT3 pathway.
Such a phenomenonmay be of substantial importance.Thus,
it may lead to counteraction of the plasticity changes seen
in discrete pain networks leading to chronic pain [99]. If so,
coactivation of MOR and CB1 is the way to go since single
activation of the protomers leads to increases in plasticity
[98]. It should be considered that RTK can also be involved
in these plasticity responses forming a heterotrimer with the
CB1-MOR heterodimer making possible integration of trans-
mission and trophic signaling already at the plasma mem-
brane level [8, 36, 37, 100].
15. On the Existence of
CB1-D2R and D4R-MOR Heteromers
and Their Role in Addiction
There exist indications for the existence also of a CB1-D2R
heteromer in which A2AR may participate [101, 102] in
the striatopallidal GABA neurons, a key pathway in reward
mechanisms. D2R play a major role in cocaine addiction
development where the receptor-receptor interactions in
CB1-D2R heteromers may exert beneficial actions. During a
state of dominance of D2R activation, a negative-feedback
regulation ofD2R remains through theD2R-mediated release
of anandamide inducing an antagonistic CB1-D2R inter-
action which counteract the exaggerated activation of the
D2Rs. In this heteromer, through allosteric receptor-receptor
interactions, CB1 may also become coupled to Gs [101, 103]
to reduce the downstate induced by the excessive D2R
activation, contributing to addiction development.
There may also exist D4R-MOR heteromers in the
nucleus accumbens and dorsal striatum of relevance to
the treatment of addiction (Figure 3). Thus, D4R activation
decreases MOR IR in the striatal islands [104] and D4R
can modulate the affinity of MOR in striatum. Furthermore,
D4R activation counteracts the morphine induced increases
in the striatal expression of the transcription factors c-Fos,
deltaFosB and P-CREB [105]. These results can be explained
on the existence of antagonistic D4R-MOR interactions in
striatal D4R-MOR heteromers [106]. D4R-D2R heteromers
[107] and D4R homomers [108] have previously been shown
to exist. It will be of interest to evaluate if acupuncture treat-
ment in drug addiction can modulate the striatal CB1-D2R
and D4R-MOR heteromers and their antagonistic receptor-
receptor interactions.
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16. MOR Isoform 1D (MOR1D)
Heterodimerizes with
Gastrin-Releasing Peptide Receptor
(GRPR) in the Spinal Cord: A Key Role
in Morphine Induced Itch
In 1983 we discovered neuronal gastrin releasing peptide
(GRP) IR in the rat CNS [109]. In the revision we were forced
to add also bombesin like IR in the description of the IR
since the reviewer claimed it was not possible to fully exclude
this possibility. GRP was discovered in porcine nonantral
gastric tissue [110]. C-terminal specific antisynthetic porcine
GRP sera R-6902 and R-6903 were used showing GRP-like IR
in brain tissue extracts. As control was used an antibombe-
sin (BN) serum with the major immunological determinant
residing in the 6-7 peptide sequence of BN which is lack-
ing GRP. The results favored the existence of GRP-like IR
terminals especially found in the marginal layer and in the
substantia gelatinosa of the dorsal horn having a codistri-
bution with SP IR terminals.
Sun and Chen discovered that GRPR mediates the itch
sensation in the spinal cord which brought GRP transmission
into the spotlight [111]. In 2011 Liu et al.’s group [112]
demonstrated coexpression of GRPR and the MOR isofom
MOR1D in Lamina I of the spinal cord but not with theMOR1
isoform.
MOR1D was shown to heterodimerize with GRPR in the
spinal cord, relaying itch information [112]. Spinal opiates
were found to produce itch through MOR1D-GRPR het-
eromerization leading to cross activation of GRPR signaling
(PLC-𝛽/IP3-dependent Ca2+ signaling pathway) (Figure 3).
They showed that morphine triggers internalization of both
GRPR and MOR1D, while GRP specifically triggers GRPR
internalization and morphine-independent scratching [112].
The data suggest that opioid-induced itch is an active
process concomitant with but independent of opioid anal-
gesia, occurring via the unidirectional cross-activation of
GRPR signaling by MOR1D-GRPR heterodimerization. The
evidence demonstrates that the C-Terminus of theMOR1D is
critical for the MOR1D-GRPR heterodimer formation. The
difference between MOR1 and MOR1D isoforms lies in a
motif consisting of seven amino acids (RNEEPSS) located in
the C-terminus of the MOR1D.
To test the spinal functions of the heteromer, a Tat-fusion
peptide (Tat-MOR1D CT) was synthesized. The Tat-motif
(YGRKKRRQRRR) belong to a trans-activating domain of a
HIV protein that can permeate the cell membrane allowing,
after intrathecally injection into the spinal cord, the intro-
duction of the fused MORD1 C-terminal (RNEEPSS motif)
into the cells. Introduction of the Tat-MOR1D CT permits its
competitionwithMOR1D for physical contacts withGRPR in
vivo. It specifically blockedmorphine induced scratcheswhile
leaving GRP induced scratches intact, morphine induced
analgesia unaltered and a reduction in the coimmunoprecip-
itation of MOR1D-GRPR levels.
New insights into opioid-induced itch prevention was in
this way obtained. They also demonstrated that molecular
and pharmacologic inhibition of PLC-𝛽3 and IP3R3, two
downstream effectors of GRPR, specifically blocked mor-
phine induced scratches but not morphine induced analgesia
[112]. Based on these observations it would be of high interest
to test if acupuncture can counteract the formation of the
MOR1D-GRPRheteromers.Thiswould give a biological basis
for its use in treatment of itch.
17. Nociceptors in the Peripheral
Nervous System and Their TRPA1-TRPV1
Heteromeric Complexes
Of high interest are the peripheral nociceptors and their
Transient receptor potential cation channel, subfamily A,
member 1 (TRPA1)-Transient receptor potential cation chan-
nel, subfamily V, member 1 (TRPV1) heteromeric complexes.
TRPV1, one heat nociceptor, is the most famous one, since
it represents the capsaicin or vanilloid receptor, activated by
ingredients in “hot” chili peppers [7]. TRPA1 is a chemical
nociceptor. It is a receptor for pungent ingredients inmustard
and garlic plants, isothiocyanates and thiosulfinates. These
nociceptor terminals also express a host of sodium channels
and potassium channels (such as TRAAK and TREK-1) that
modulate nociceptor excitability and/or contribute to action
potential propagation [7].The capsaicin TRPV1 is a nonselec-
tive cation channel that is structurally related to members of
the TRP family of ion channels [113].Themembrane topology
and domain structure of TRPV1 have been predicted. TRPV1
ion channel has high Ca2+ permeability and the capsaicin
activation of this channel kills the cells.
Bymeans of acceptor bleaching FRET, a direct interaction
between TRPA1 and TRPV1 on the plasma membrane was
observed [114]. The increase in donor emission between
TRPA1 and TRPV1 in the plasma membrane is just as large
as between the corresponding homomers TRPA1-TRPA1 and
TRPV1-TRPV1 as has been demonstrated by measurement of
the FRET signal efficiency.
Mustard oil activates single channel currents in TRPA1
and TRPA1-TRPV1 expressing CHO cells. Vigorous activa-
tion of channels in TRPA1 and TRPA1-TRPV1 expressing cells
was observed but not in untransfected CHO cells with multi-
ple conductance states, performed in cell-attached configura-
tion in voltage clamp mode [114]. However, differences of the
current voltage relationships have been found in the single
channel activities of TRPA1 alone and TRPA1-TRPV1 hetero-
mers. The single channel mustard oil induced conductance
(IMO) current-voltage I-V relationships for TRPA1-contain-
ing cells showed hardly any rectification. In contrast, the
TRPA1-TRPV1 channel heteromers resulted in an outward
rectification with a high conductance slope, for the out-
ward versus the inward parts of the I-V curve, respectively.
Thus, the ion channel function becomes altered through the
TRPA1-TRPV1 heteromerization. Also, results on the prop-
erties of single channel mustard oil induced conductances
(IMO) in TRPA1 in WT and TRPV1 KO sensory neurons
validated these findings. IMO exhibited substantially greater
activity at positive voltages in WT neurons compared with
TRPV1 KO neurons [114].
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These results support the hypothesis that TRPV1 and
TRPA1 in nociceptors may form a heteromeric receptor ion
channel complex and that TRPV1 can influence intrinsic
characteristics of the TRPA1 channel also independent of
intracellular calcium [114, 115]. Transmission of inflamma-
tory stimuli by nociceptors (namely damage-sensing sensory
neurons) is also mutually controlled by TRPA1 and TRPV1
channels. This functional interaction between TRPV1 and
TRPA1 could occur indirectly via recruitment of secondmes-
sengers, such as intracellular Ca2+ and/or directly, involving
allosteric receptor-receptor interactions between these recep-
tor channels within a heteromeric complex.
The demonstrated pharmacological cross-desensitization
between capsaicin and mustard oil responses can involve
desensitization of TRPA1 and TRPV1 ion channel activities in
their heteromeric complexes which may contribute to inhibi-
tion of nociceptor signaling leading to antihyperalgesia and
antinociception [114, 115]. One mechanism for the antinoci-
ceptive actions of acupuncture along meridians may be that
it enhances the cross-desensitization of the TRPA1-TRPV1
heteromeric complexes within the nociceptors located along
these meridians. This process may inter alia involve changes
in the flow of volume transmission signals in channels con-
taining extracellular fluid and nociceptors along the meridi-
ans modulating the sensitivity of the nociceptors [22, 82].
18. Ionotropic Cannabinoid
Receptors in Peripheral Antinociception
and Antihyperalgesia
There is also a role of ionotropic cannabinoid receptors
(ICR) in peripheral antinociception and antihyperalgesia.
The known ICRs are members of the family of transient
receptor potential channels (TRP) and remarkably include
TRPV1, TRPV2, TRPV4, TRPM8, and TRPA1 (see above).
The majority of ICRs are expressed in nociceptive sensory
neurons, which can detect and respond to noxious mechani-
cal, thermal and chemical stimuli. Nevertheless, the cannabi-
noids produce a profound antihyperalgesia and the mecha-
nism has not yet been established [115].
One possible hypothesis addressing this issue is that par-
tial activation of ICRs does not necessarily generate excitation
(i.e., action potential) of nociceptors. From this perspective,
it is interesting that cannabinoids are not full agonists for
TRP channels. Indeed, cannabinoids typically evoke a slow
generation of small inward currents and Ca2+ accumulation.
As a result, cannabinoid-gated responses might not reach
the threshold levels required to excite nociceptors. More-
over, slow depolarization of nociceptor membrane potentials
might lead to inactivation of voltage gated channels that, in
turn, inhibits the generation of action potentials.
To understand how activation of ICRs leads to inhibition
of nociceptors, molecular mechanisms of desensitization of
TRP channels by ICR-activating cannabinoids have been
studied [115]. The results indicate that cross desensitization
between the TRPA1 and TRPV1 channels (see also above) in
sensory neurons can involve multiple separate mechanisms.
Cannabinoidsmay desensitize TRPV1 channels via activation
of calcineurin and dephosphorylation of the ion channel.
Homologous desensitization of TRPV1 can occur by applica-
tion of TRPV1-selective cannabinoids, and heterologous
desensitization of TRPV1 can occur by administration of
TRPA1-selective cannabinoids (e.g., WIN55212). Cannabi-
noids can also desensitize TRPA1 via activation of a calcium-
independent pathway.
Based on the existence of TRPA1-TRPV1 heteromeric
complexes we may also hypothesize the following mecha-
nism: Ionotropic cannabinoids can activate antagonistic allo-
steric channel-channel interactions in such types of hetero-
meric complexes. This allosteric mechanism especially upon
coactivation of the two TRP channels by selective ionotropic
cannabinoids may produce cross-desensitization of the
two nociceptor channels leading to antinociception and
antihyperalgesia. The ionotropic cannabinoids may best
be regarded as negative allosteric modulators of TRPA1-
TRPV1 heteromeric complexes and other types of TRP het-
eromeric complexes. It is presently unknown to which extent
metabotropic CB1 and CB2 may participate in the modula-
tion of the peripheral nociceptors and in the mediation of the
actions of the ionotropic cannabinoids. A dynamic interplay
between CB1/CB2 and TRP channels as to heteromerization
is however, an interesting possibility.
Other mechanisms for acupuncture induced analgesia
likely also exist since analgesic effects also develop in distant
parts of the body. There exists a mechanism called diffuse
noxious inhibitory control (DNIC)which results in reduction
of pain from the experimental noxious stimulus when a noci-
ceptive stimulus is applied to a region remote to the test area
[20, 116, 117]. DNIC has inter alia been shown to be activated
in experimental peripheral mononeuropathy [118] where
peripheral mechanisms may mainly be involved like sensiti-
zation of damaged nerve fibers. However, acupuncture can
activate pathways involved in DNIC as found in studies on
trigeminal caudalis neurons in rats [119]. However, lower pain
intensities are used in human acupuncturewhichmay explain
why the analgesic effects of acupuncture in humans are less
than a DNIC effect of a painful noninvasive stimulus [116].
It should also be noted that sensory neuropeptides like
substance Pmay be released fromnociceptors upon acupunc-
ture and both acupuncture and sensory neuropeptides
increase cutaneous blood flow [120]. It is of particular interest
that somatostatin peptides may produce systemic analgesic
effects [121].Thus, somatostatin can produce inhibition of the
cross-excitation between adjacent primary afferent terminals
in rats induced by antidromic stimulation of primary affer-
ents leading to inhibition of peripheral hyperalgesia. There-
fore, one additional mechanism for acupuncture analgesia
should be considered namely that somatostatin can be
released by acupuncture from sensory nerve terminals along
the meridians. It may then diffuse and flow along the inter-
stitial fluid channels of the meridians for short (extrasynaptic
mode) and/or long distances of volume transmission [122] to
activate somatostatin receptors located on the plasma mem-
brane of the nociceptors to reduce their firing and produce
reduction of pain.The findings of Guo et al. (2008) [121] indi-
cate that released somatostatin may also use the surrounding
vascular beds to reach via the circulation adjacent primary
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afferents and also via this mode of communication produce
peripheral analgesic effects via activation of somatostatin
receptors.
19. Future Directions
The role of the receptor heteromers in pain modulation may
be studied along the following lines.
(i) Understanding the role of MOR-DOR, MOR-KOR,
alpha-2AAR-MOR, and CB1-MOR heteromers in key
pain circuits in the CNS. Of special interest will be
to outline the role of opioid receptor heteromers as a
target for the treatment of pain including acupuncture
and the role of MOR1D-GRPR heteromer in itch and
as a target for the anti-pruritus actions of acupunc-
ture.
(ii) Understanding the role of TRPA1-TRPV1 heteromeric
ion channel complexes in nociceptor function and
their role in the antinociceptive and antihyperalgesic
actions of cannabinoids.
(iii) Characterization of the receptor interfaces in distinct
opioid receptor and TRPA1-TRPV1 heteromers and
putative ERs-MOR-KORheteromeric complexes.The
receptor interface is a novel target enabling modula-
tion of the allosteric receptor-receptor interactions.
(iv) Understanding the pharmacology of the above recep-
tor heteromers. A major targets for the therapeutic
effects of antinociceptive drugs which may mediate
side effects.
(v) Understanding the link of potential changes in dis-
tinct opioid receptor and TRPA1-TRPV1 heteromer
structure and function to plasticity changes in the
pain pathways in chronic pain syndromes. Discovery
of novel key receptor heteromers is still to come.
(vi) Finally, discrete heteromers may also be targets for
chemical ingredients mediating the medicinal prop-
erties and the side-effects of plants that is, herbal
medicine.
Glossary
The usage of terms in medicine often varies widely. For this
reason, it is convenient and helpful to authors and read-
ers if words can be used with an agreement in their tech-
nical meaning. The definition provided in this Glossary are
intended to be specific andexplanatory and to serve as a useful
framework, not as a constraint on feature development for
memberswhowork in the field of pain or are interested in this
review article topics (all definitions are taken from Andreas
Kopf Guide Pain Management in Low-Resource Settings,
International Association for the Study of Pain).
Acupuncture. Acupuncture is a procedure involving the
stimulation or inhibition at ananatomical location on or in
the skin by a variety of techniques. A number of effects
on painphysiology have been identified, the most important
being the activation of the endogenousopioid system and the
spinal modulation of pain signaling through activation of
touch fibers (A𝛽 fibers).
Analgesia. Absence of pain in response to stimulation that
would normally be painful. The stimulus is defined by its
usual subjective effects.
Hyperalgesia. An increased response to a stimulus that in
normally painful. Hyperalgesia reflects increased pain on
supra-threshold stimulation. For pain evoked by stimuli that
usuallyare not painful, the term allodynia is preferred, while
hyperalgesia is more appropriately usedfor cases with an
increased response at a normal threshold, or at an increased
threshold, such asin patients with neuropathy. It should
also be recognized that with allodynia the stimulus andthe
response are in different modes, whereas with hyperalgesia
they are in the same mode.
Meridian. In the Chinese medicine acupuncture means each
of a set of pathways in thebody along which vital energy is
said to flow. There are twelve such pathways associated with
specific organs.
Nociception. Nociception is the sensory component of pain. It
encompasses the peripheral and the central neuronal events
following the transduction of damaging mechanical, chem-
icalor thermal stimulation of sensory neurons (nociceptors).
Nociceptor. A receptor preferentially sensitive to a noxious
stimulus or to a stimulus thatwould become noxious if
prolonged. Often called a pain receptor.
Noxious Stimulus. A noxious stimulus is one that is damaging
to normal tissue.
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